Effects of olmesartan on arterial stiffness in rats with chronic renal failure

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Chuang, Yao Chen ^a   Wu, Ming Shiou ^b   Su, Yi Kai ^b   Fang, Kwang Ming ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL YUNLIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Advanced glycation end products; Aortic impedance analysis; Chronic renal failure; Diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CREATININE; NITROGEN; OLMESARTAN; PLACEBO; REACTIVE OXYGEN METABOLITE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; RAT; UREA NITROGEN BLOOD LEVEL; VASCULAR RESISTANCE; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIOXIDANTS; AORTA; BLOOD UREA NITROGEN; CREATININE; DISEASE MODELS, ANIMAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; MALE; MALONDIALDEHYDE; NEPHRECTOMY; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TETRAZOLES; VASCULAR STIFFNESS;

EID: 84862198327     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-66     Document Type: Article

References (50)

1. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. Postgrad Med J 2010, 86(1019):817-823.
2. Ford ML, Tomlinson LA, Chapman TP, Rajkumar C, Holt SG. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 2010, 55(5):1110-1115. 10.1161/HYPERTENSIONAHA.109.143024, 20212269.
3. Henle T, Miyata T. Advanced glycation end products in uremia. Adv Ren Replace Ther 2003, 10(4):321-331. 10.1053/j.arrt.2003.08.006, 14681861.
4. Meerwaldt R, Zeebregts CJ, Navis G, Hillebrands JL, Lefrandt JD, Smit AJ. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 2009, 53(1):138-150. 10.1053/j.ajkd.2008.08.031, 19036487.
5. Sajithlal GB, Chithra P, Chandrakasan G. Advanced glycation end products induce crosslinking of collagen in vitro. Biochim Biophys Acta 1998, 1407(3):215-224. 10.1016/S0925-4439(98)00043-X, 9748585.
6. Cooper ME. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 2004, 17(12 Pt 2):31S-38S.
7. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162(4):1123-1137. 10.1016/S0002-9440(10)63909-0, 1851245, 12651605.
8. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006, 21(2):299-313. 10.1093/ndt/gfi210, 16263740.
9. Yue WS, Lau KK, Siu CW, Wang M, Yan GH, Yiu KH, Tse HF. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2011, 10:113. 10.1186/1475-2840-10-113, 3258289, 22185563.
10. Lijnen PJ, Petrov VV, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. Journal of the Renin-Angiotensin-Aldosterone system: JRAAS 2001, 2(2):117-122.
11. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. Journal of the American Society of Nephrology: JASN 2002, 13(10):2478-2487. 10.1097/01.ASN.0000032418.67267.F2, 12239236.
12. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007, 323(1):85-93. 10.1124/jpet.107.123638, 17636006.
13. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321(7274):1440-1444. 10.1136/bmj.321.7274.1440, 27545, 11110735.
14. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358(23):2433-2446. 10.1056/NEJMoa0708379, 18525041.
15. Busch M, Franke S, Wolf G, Rohde RD, Stein G. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 2008, 108(4):c291-c297. 10.1159/000127838, 18434751.
16. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. Journal of the American Society of Nephrology: JASN 2005, 16(4):1135-1140. 10.1681/ASN.2004100852, 15716329.
17. Kadowaki D, Anraku M, Tasaki Y, Taguchi K, Shimoishi K, Seo H, Hirata S, Maruyama T, Otagiri M. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats. Biol Pharm Bull 2009, 32(12):2041-2045. 10.1248/bpb.32.2041, 19952425.
18. Navar LG. The role of the kidneys in hypertension. J Clin Hypertens (Greenwich) 2005, 7(9):542-549.
19. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86(3):747-803. 10.1152/physrev.00036.2005, 16816138.
20. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364(10):907-917. 10.1056/NEJMoa1007994, 21388309.
21. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. Journal of the American Society of Nephrology: JASN 2002, 13(12):2916-2929. 10.1097/01.ASN.0000034909.10994.8A, 12444210.
22. Chang KC, Hsu KL, Tseng YZ. Effects of diabetes and gender on mechanical properties of the arterial system in rats: aortic impedance analysis. Exp Biol Med (Maywood) 2003, 228(1):70-78.
23. Mitchell GF, Pfeffer MA, Westerhof N, Pfeffer JM. Measurement of aortic input impedance in rats. Am J Physiol 1994, 267(5 Pt 2):H1907-H1915.
24. Milnor WR. Hemodynamics 1989, Baltimore: Williams & Wilkins Co.
25. Nichols WW, O'Rourke MF. McDonald's Blood Flow in Arteries 1998, London: Arnold.
26. Gaballa MA, Raya TE, Hoover CA, Goldman S. Effects of endothelial and inducible nitric oxide synthases inhibition on circulatory function in rats after myocardial infarction. Cardiovasc Res 1999, 42(3):627-635. 10.1016/S0008-6363(98)00343-5, 10533602.
27. Huijberts MS, Wolffenbuttel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P, Levy BI. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993, 92(3):1407-1411. 10.1172/JCI116716, 288284, 8376593.
28. Liu Z, Brin KP, Yin FC. Estimation of total arterial compliance: an improved method and evaluation of current methods. Am J Physiol 1986, 251(3 Pt 2):H588-H600.
29. Laxminarayan S, Sipkema P, Westerhof N. Characterization of the arterial system in the time domain. IEEE Trans Biomed Eng 1978, 25(2):177-184.
30. Westerhof N, Sipkema P, van den Bos GC, Elzinga G. Forward and backward waves in the arterial system. Cardiovasc Res 1972, 6(6):648-656. 10.1093/cvr/6.6.648, 4656472.
31. Turk Z, Misur I, Turk N, Benko B. Rat tissue collagen modified by advanced glycation: correlation with duration of diabetes and glycemic control. Clin Chem Lab Med 1999, 37(8):813-820.
32. Lapolla A, Brancia FL, Bereszczak J, Fedele D, Baccarin L, Seraglia R, Traldi P. Off-line liquid chromatography-MALDI by with various matrices and tandem mass spectrometry for analysis of glycated human serum albumin tryptic peptides. Mol Nutr Food Res 2007, 51(4):456-461. 10.1002/mnfr.200600291, 17357982.
33. Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, Schwandt P, Ludwig M. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007, 1(2):97-106. 10.1177/1753944707085982, 19124398.
34. Nishida Y, Takahashi Y, Nakayama T, Soma M, Asai S. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol 2011, 10:74. 10.1186/1475-2840-10-74, 3163179, 21827713.
35. Ono M, Fukuda M, Miura T, Mizuno M, Kato Y, Sato R, Naito T, Togawa H, Sasakawa Y, Tomonari T, et al. Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan. Journal of the renin-angiotensin-aldosterone system: JRAAS 2012, 13(2):239-243. 10.1177/1470320311434817, 22333486.
36. Zhang H, Ma G, Yao Y, Qian H, Li W, Chen X, Jiang W, Zheng R. Olmesartan Attenuates the Impairment of Endothelial Cells Induced by Oxidized Low Density Lipoprotein through Downregulating Expression of LOX-1. Int J Mol Sci 2012, 13(2):1512-1523. 10.3390/ijms13021512, 3291974, 22408405.
37. Brousil JA, Burke JM. Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 2003, 25(4):1041-1055. 10.1016/S0149-2918(03)80066-8, 12809956.
38. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003, 63(1):179-185. 10.1046/j.1523-1755.2003.00702.x, 12472781.
39. Fujimoto S, Satoh M, Horike H, Hatta H, Haruna Y, Kobayashi S, Namikoshi T, Arakawa S, Tomita N, Kashihara N. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res 2008, 31(2):305-313. 10.1291/hypres.31.305, 18360051.
40. Chang KC, Tseng CD, Wu MS, Liang JT, Tsai MS, Cho YL, Tseng YZ. Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes. Eur J Clin Invest 2006, 36(8):528-535. 10.1111/j.1365-2362.2006.01672.x, 16893374.
41. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003, 21(1):3-12. 10.1097/00004872-200301000-00002, 12544424.
42. Bohlender J, Franke S, Sommer M, Stein G. Advanced glycation end products: a possible link to angiotensin in an animal model. Ann N Y Acad Sci 2005, 1043:681-684. 10.1196/annals.1333.078, 16037293.
43. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008, 7:29. 10.1186/1475-2840-7-29, 2569910, 18840258.
44. Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007, 30(3):670-676. 10.2337/dc06-1508, 17327339.
45. Kuo HT, Kuo MC, Chiu YW, Chang JM, Guh JY, Chen HC. Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis. Eur J Clin Invest 2005, 35(4):245-250. 10.1111/j.1365-2362.2005.01488.x, 15816993.
46. Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl 2007, 106:S17-S26.
47. Miyata T, van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 2003, 419(1):50-54. 10.1016/j.abb.2003.08.010, 14568008.
48. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005, 289(4):F645-F659. 10.1152/ajprenal.00398.2004, 16159899.
49. Thornalley PJ. Glycation free adduct accumulation in renal disease: the new AGE. Pediatr Nephrol 2005, 20(11):1515-1522. 10.1007/s00467-005-2011-9, 16133053.
50. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005, 16(12):3631-3641. 10.1681/ASN.2005050522, 16236804.